CAR-T therapies have shown remarkable success in immuno-oncology and are now being explored for non-oncology indications, including autoimmune diseases. In order to meet the growing demand for these therapies, automated, closed, modular, and all-in-one systems must be considered.

This infographic gives an easily digestible visual guide to three CD19 CAR-T cell manufacturing pathways (the G-Rex® System, the Cocoon® platform, and the CliniMACS Prodigy® System), using differing platforms, including experimental data on viability, purity, and yield for these automated, closed, modular, and all-in-one systems.

About OmniaBio
As a dedicated cell and gene therapy CDMO, OmniaBio's vision is to manufacture a disease-free future. Headquartered in Ontario, Canada, our core values of collaborative partnership converge with deep industry experience and innovation using the latest technologies to drive the future of cell and gene therapy manufacturing.